Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GM1 Prophylaxis for CIPN in Breast Cancer (Gypsophila)
NCT06994507Phase 3Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- Aug 2025
- Primary completion
- Sep 2026
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of monosialotetrahexosylganglioside in chemotherapy-induced peripheral neuropathy (CIPN), sponsored by Qilu Pharmaceutical. Started Aug 2025; status: recruiting.
02
Drugs
monosialotetrahexosylganglioside
03
Conditions
chemotherapy-induced peripheral neuropathy (CIPN)
Beyond the preview
Go deeper on NCT06994507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06994507.